CR20220318A - USING A KV7 POTASSIUM CANAL OPENER TO TREAT PAIN - Google Patents

USING A KV7 POTASSIUM CANAL OPENER TO TREAT PAIN

Info

Publication number
CR20220318A
CR20220318A CR20220318A CR20220318A CR20220318A CR 20220318 A CR20220318 A CR 20220318A CR 20220318 A CR20220318 A CR 20220318A CR 20220318 A CR20220318 A CR 20220318A CR 20220318 A CR20220318 A CR 20220318A
Authority
CR
Costa Rica
Prior art keywords
treat pain
methods
opener
subject
compound
Prior art date
Application number
CR20220318A
Other languages
Spanish (es)
Inventor
Gregory N Beatch
Jr James Philip Johnson
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of CR20220318A publication Critical patent/CR20220318A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
  • Light Guides In General And Applications Therefor (AREA)

Abstract

En ciertas modalidades, la presente descripción se dirige a métodos para tratar el dolor en un sujeto, como un humano, en donde los métodos comprenden administrar oralmente una cantidad efectiva terapéuticamente de <em>N</em>-[4-(6-fluoro-3,4-dihidro-1<em>H</em>-isoquinolin-2-il)-2,6-dimetilfenil]-3,3-dimetilbutanamida (Compuesto A), al sujeto en necesidad de esta. La presente descripción se dirige además a varios métodos mejorados de terapia y administración del Compuesto A.In certain embodiments, the present disclosure is directed to methods of treating pain in a subject, such as a human, wherein the methods comprise orally administering a therapeutically effective amount of <em>N</em>-[4-(6- fluoro-3,4-dihydro-1<em>H</em>-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the subject in need thereof. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

CR20220318A 2019-12-06 2020-12-04 USING A KV7 POTASSIUM CANAL OPENER TO TREAT PAIN CR20220318A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945093P 2019-12-06 2019-12-06
US201962948010P 2019-12-13 2019-12-13
PCT/US2020/063471 WO2021113757A1 (en) 2019-12-06 2020-12-04 Use of a kv7 potassium channel opener for treating pain

Publications (1)

Publication Number Publication Date
CR20220318A true CR20220318A (en) 2022-10-07

Family

ID=73856375

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220318A CR20220318A (en) 2019-12-06 2020-12-04 USING A KV7 POTASSIUM CANAL OPENER TO TREAT PAIN

Country Status (14)

Country Link
EP (1) EP4069211A1 (en)
JP (1) JP2023504166A (en)
KR (1) KR20220113411A (en)
CN (1) CN114786658A (en)
AU (1) AU2020397173A1 (en)
BR (1) BR112022010733A2 (en)
CA (1) CA3159436A1 (en)
CL (1) CL2022001477A1 (en)
CR (1) CR20220318A (en)
IL (1) IL293504A (en)
MX (1) MX2022006877A (en)
PE (1) PE20221169A1 (en)
TW (1) TW202133847A (en)
WO (1) WO2021113757A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4074696A4 (en) 2021-10-27 2024-01-31 Shanghai Zhimeng Biopharma, Inc. Compound as potassium channel regulator, and preparation and use thereof
CN113698345B (en) * 2021-10-27 2022-02-01 上海挚盟医药科技有限公司 Compounds as potassium channel modulators, their preparation and use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
DK2061465T3 (en) 2006-08-23 2013-07-08 Valeant Pharmaceuticals Int Derivatives of 4- (N-azacycloalkyl) anilides as potassium channel modulators
WO2013067591A1 (en) * 2011-11-10 2013-05-16 Relevare Australia Pty Ltd Topical formulations for pain management
US9248122B2 (en) * 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
ES2964409T3 (en) * 2018-05-11 2024-04-05 Xenon Pharmaceuticals Inc Procedures to enhance the bioavailability and exposure of a voltage-gated potassium channel opener

Also Published As

Publication number Publication date
CA3159436A1 (en) 2021-06-10
TW202133847A (en) 2021-09-16
IL293504A (en) 2022-08-01
JP2023504166A (en) 2023-02-01
PE20221169A1 (en) 2022-07-25
CL2022001477A1 (en) 2023-04-28
KR20220113411A (en) 2022-08-12
BR112022010733A2 (en) 2022-08-23
AU2020397173A1 (en) 2022-06-23
CN114786658A (en) 2022-07-22
EP4069211A1 (en) 2022-10-12
MX2022006877A (en) 2022-07-11
WO2021113757A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
CL2022001477A1 (en) Using a kv7 potassium channel opener to treat pain
Muñoz Sanchez et al. The effect of 670-nm low laser therapy on herpes simplex type 1
CO2020015476A2 (en) Methods to enhance the bioavailability and exposure of a voltage-gated potassium channel opener
ECSP20080276A (en) PURINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
MX2020008258A (en) Pediatric niraparib formulations and pediatric treatment methods.
AR048705A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEXUAL DISORDERS II
MX2020009773A (en) Combination therapy.
CL2021003034A1 (en) Methods of treatment of sjögren&#39;s syndrome using a bruton&#39;s tyrosine kinase inhibitor
RU2013103334A (en) COMPOSITIONS CONTAINING EXTRACTS OF ECHINACEA ANGUSTIFOLIA AND ZINGIBER OFFICINALE WHICH USE TO REDUCE INFLAMMATION AND PERIPHERAL PAIN
CO2023000703A2 (en) Cancer treatment methods using heteroaryl-biphenyl-amide derivatives
BR112021016833A2 (en) Compounds with ferroptosis-inducing activity and methods of their use
CL2021003032A1 (en) Methods of treating chronic spontaneous urticaria using a Bruton&#39;s tyrosine kinase inhibitor.
CL2022002566A1 (en) Low-dose brimonidine combinations and uses thereof. (Divisional Application of 201903572)
CO2022008001A2 (en) Methods for treating depressive disorders
EA201992759A1 (en) ASSOCIATION INCLUDING OXYGEN AND HYALURONIC ACID, FOR LOCAL VAGINAL USE
CL2023002321A1 (en) Voltage-activated potassium channel opener for use in the treatment of anhedonia.
Tang et al. Eriodictyol inhibits the growth of CNE1 human nasopharyngeal cancer growth by targeting MEK/ERK signalling pathway, inducing cellular autophagy and inhibition of cell migration and invasion
Ning et al. The successful treatment of flat warts with auricular acupuncture
EA202092077A1 (en) LOCAL COMPOSITIONS CONTAINING STRONZIUM AND METHYLSULPHONYLMETHANE (MSM) AND METHODS OF TREATMENT
RU2620336C1 (en) Treatment method of chronically non-healing wounds
AR114854A1 (en) METHODS FOR THE TREATMENT OF CANCER
CO2023011948A2 (en) Conjoint therapy for the treatment of seizure disorders
AR026506A1 (en) A MEDICATION FOR THE PREVENTION AND TREATMENT OF SEXUAL DYSFUNCTION
CL2022001476A1 (en) Use of reboxetine to treat disorders of the nervous system
PE20230181A1 (en) USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS